Owner Cequent Pharmaceuticals, Inc.

Convention US 17 January 2007 77/084,336

Service Cullen & Co

Various Convention priority claimed: 17 January 2007, United States of America, No. 77/084,336 in respect of BIOPHARMACEUTICALS, BIOLOGICS, AND RNA MOLECULES AND MOLECULAR AGGREGATES, AND PREPARATIONS THEREOF, FOR THE REGULATION, MODULATION, EXPRESSION, AND INACT

Filing Date 27 June 2007

Class 1 Biopharmaceuticals, biologics, and rna molecules and molecular aggregates, and preparations thereof, for the regulation, modulation, expression, and inactivation of individual mammalian and human genes for use in the fields of molecular and pharmaceutical research and development and scientific research of mammalian and human diseases

Class 5 Biopharmaceuticals, biologics, and RNA molecules and molecular aggregates, and preparations thereof, for the regulation, modulation, expression, and inactivation of individual mammalian and human genes for use in the fields of clinical diagnosis, treatment, and gene-targeted therapy of human and veterinary diseases

Class 42 Scientific and technological research and development services, namely, providing biological and pharmaceutical research and development relating to biopharmaceuticals, biologics, and RNA molecules and molecular aggregates, and preparations thereof, for the regulation, modulation, expression, and inactivation of individual mammalian and human genes used for diagnosis, treatment, and gene-targeted therapy of human and veterinary diseases and for molecular and pharmaceutical research and development and scientific research of mammalian and human diseases